Joseph Shulman - 11 Nov 2024 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
Chief Technical Officer
Signature
/s/ Stephen Vander Stoep as Attorney-in-Fact for Joseph Shulman
Issuer symbol
RYTM
Transactions as of
11 Nov 2024
Net transactions value
-$714,581
Form type
4
Filing time
13 Nov 2024, 21:02:57 UTC
Previous filing
18 Jul 2024
Next filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise $54,189 +7,969 $6.80 7,969 11 Nov 2024 Direct
transaction RYTM Common Stock Options Exercise $113,571 +5,312 +67% $21.38 13,281 11 Nov 2024 Direct
transaction RYTM Common Stock Sale $434,075 -6,604 -50% $65.73 6,677 11 Nov 2024 Direct F1, F2
transaction RYTM Common Stock Sale $400,782 -5,977 -90% $67.05 700 11 Nov 2024 Direct F1, F3
transaction RYTM Common Stock Sale $47,484 -700 -100% $67.83 0 11 Nov 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Stock Option (right to buy) Options Exercise $0 -7,969 -29% $0.000000 19,922 11 Nov 2024 Common Stock 7,969 $6.80 Direct F5
transaction RYTM Stock Option (right to buy) Options Exercise $0 -5,312 -100% $0.000000 0 11 Nov 2024 Common Stock 5,312 $21.38 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on August 8, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $65.35 to $66.3499. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $66.5 to $66.4999. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $67.51 to $68.5099. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
F6 The stock options were granted on July 27, 2020. 25% of the shares subject to the option vested and became exercisable on July 27, 2021 and the remaining 75% of the shares subject to the option shall vest and become exercisable in 12 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer thereafter.